BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oba A, Inoue Y, Ono Y, Irie S, Sato T, Mise Y, Ito H, Takahashi Y, Saiura A. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Langenbecks Arch Surg 2020;405:35-41. [DOI: 10.1007/s00423-019-01846-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Liu X, Lu N, Chen Y, Zhang X, Guo C, Xiao W, Xue X, Sun K, Wang M, Gao S, Shen Y, Zhang M, Wu J, Que R, Yu J, Bai X, Liang T. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery. BMC Cancer 2023;23:49. [PMID: 36641427 DOI: 10.1186/s12885-023-10529-7] [Reference Citation Analysis]
2 Hashimoto D, Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Ishida M, Matsui Y, Shibata N, Boku S, Katsushima U, Ikeura T, Sekimoto M. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal adenocarcinoma. Pancreatology 2023;23:73-81. [PMID: 36494309 DOI: 10.1016/j.pan.2022.11.012] [Reference Citation Analysis]
3 Li X, Liu X, Lu N, Chen Y, Zhang X, Guo C, Xiao W, Xue X, Sun K, Wang M, Gao S, Shen Y, Zhang M, Wu J, Que R, Yu J, Bai X, Liang T. Normalization of the Tumor Marker and a Clear Resection Margin Affect Progression-Free Survival of Patients with Unresectable Pancreatic Cancer who have Undergone Conversion Surgery.. [DOI: 10.21203/rs.3.rs-1861769/v1] [Reference Citation Analysis]
4 Takeda T, Sasaki T, Okamoto T, Kasuga A, Matsuyama M, Ozaka M, Inoue Y, Takahashi Y, Saiura A, Sasahira N. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat Sci 2022. [PMID: 35593731 DOI: 10.1002/jhbp.1184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35294658 DOI: 10.1245/s10434-022-11503-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hayashi K, Ono Y, Takamatsu M, Oba A, Ito H, Sato T, Inoue Y, Saiura A, Takahashi Y. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35230581 DOI: 10.1245/s10434-022-11471-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Oba A, Kato T, Del Chiaro M, Wu YHA, Inoue Y, Takahashi Y. Pancreaticoduodenectomy with Hepatic Artery Resection. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_40] [Reference Citation Analysis]
8 Qiao PL, Gargesha M, Liu Y, Laney VEA, Hall RC, Vaidya AM, Gilmore H, Gawelek K, Scott BB, Roy D, Wilson DL, Lu ZR. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis. Magn Reson Imaging 2022;86:37-45. [PMID: 34801672 DOI: 10.1016/j.mri.2021.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4724. [PMID: 34572951 DOI: 10.3390/cancers13184724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Sakaguchi T, Satoi S, Hashimoto D, Yamamoto T, Yamaki S, Hirooka S, Ishida M, Ikeura T, Inoue K, Sekimoto M. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2021. [PMID: 34314568 DOI: 10.1002/jhbp.1026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ge JC, Tao M, Li L, Ma ZL, Jiang B, Yuan CH, Wang HY, Peng Y, Xiu DR. Nomogram and competing risk model to predict recurrence after curative surgical resection of PDAC. Pancreatology 2021:S1424-3903(21)00149-6. [PMID: 34001437 DOI: 10.1016/j.pan.2021.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Oba A, Inoue Y, Ono Y, Ishizuka N, Arakaki M, Sato T, Mise Y, Ito H, Saiura A, Takahashi Y. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. Br J Surg 2021;108:115-8. [PMID: 33711121 DOI: 10.1093/bjs/znaa111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 Okada K, Uemura K, Kondo N, Sumiyoshi T, Seo S, Otsuka H, Serikawa M, Ishii Y, Tsuboi T, Murakami Y, Takahashi S. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Pancreatology 2021;21:606-12. [PMID: 33648880 DOI: 10.1016/j.pan.2021.01.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Inoue Y, Oba A, Ono Y, Sato T, Ito H, Sasaki T, Ozaka M, Sasahira N, Takahashi Y. Neoadjuvant therapy using Gemcitabine+nab-paclitaxel for borderline resectable pancreatic head cancers. Journal of the Japan Pancreas Society 2021;36:73-81. [DOI: 10.2958/suizo.36.73] [Reference Citation Analysis]
15 Ushida Y, Inoue Y, Ito H, Oba A, Mise Y, Ono Y, Sato T, Saiura A, Takahashi Y. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology 2021;21:130-7. [PMID: 33303373 DOI: 10.1016/j.pan.2020.11.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Inoue Y, Saiura A, Oba A, Ono Y, Mise Y, Ito H, Sasaki T, Ozaka M, Sasahira N, Takahashi Y. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021;28:143-155. [PMID: 33058515 DOI: 10.1002/jhbp.844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]